On the other hand, a number of novel therapies currently used in hematologic malignancies target pathways in tumor cells that are also involved in the regulation of physiological processes in MDSCs.95 Representative examples are the PI3K and Jak/Stat signaling pathways which are therapeutic targets in lymphomas and MPNs as well as key signaling pathways in MDSCs.95 The possible effect of these target therapies on MDSCs and the possibility of an additive effect on the therapeutic outcome is an interesting field of research. The gene discussed is SOAT1; the disease is lymphoma.